FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication June 12, 2015
Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial June 7, 2015
Ligand Announces New Time for June 7th Investor Presentation and Webcast at the American Diabetes Association 75th Scientific Sessions June 5, 2015
Ligand Summarizes the Accounting Impact of the Viking Therapeutics, Inc. IPO and Updates 2015 Financial Guidance June 2, 2015
Ligand Acquires Rights to More Than 15 Fully-Funded Development Programs from Selexis SA May 11, 2015
Ligand to Present Results of LGD-6972 Phase 1b Trial at American Diabetes Association 75th Scientific Sessions on June 7th and Host Investor Presentation May 7, 2015
